|
May 7, 2008
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
May 7, 2008
Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
May 7, 2008
Nektar Therapeutics Announces First Quarter 2008 Results
April 30, 2008
Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
April 23, 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
April 14, 2008
Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
April 10, 2008
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
April 9, 2008
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
February 27, 2008
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
February 21, 2008
Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
February 12, 2008
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
February 12, 2008
Hoyoung Huh to Serve on Nektar Board of Directors
January 29, 2008
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
January 8, 2008
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
January 8, 2008
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
January 2, 2008
Nektar Therapeutics' President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
Investor Advisory |
